Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Resilience
BioCentury | Jan 13, 2025
Guest Commentary
Navigating biotech investment cycles — the true north: Guest Commentary
Biotech VC Uciane Scarlett on getting the right mix of platform-to-asset
BioCentury | Jan 4, 2025
Editor's Commentary
Letter from the Editor: Untangling reality and expectations in 2025
Can biotechs set aside exhaustion and expectations to over-deliver this year?
BioCentury | Jan 2, 2025
Editor's Commentary
Biosecure litmus test: Editor’s Commentary
Lesson one from the Biosecure Act: U.S. biotech policy must focus on bolstering the domestic bioeconomy
BioCentury | Dec 13, 2024
Product Development
Only the paranoid survive, and the CEO’s paradox, from Aoife Brennan
How CEOs are managing through uncertainty, and why ‘boring’ naked mAbs are the smart move in one field
BioCentury | Dec 10, 2024
Politics, Policy & Law
Biosecure setback & Novartis’ $1B PTC Deal: a BioCentury podcast
Plus: KCC2 activation nears inflection point
BioCentury | Dec 9, 2024
Politics, Policy & Law
Biosecure setback amid lawmakers’ push to reduce reliance on China
Defense bill places biotech under national security umbrella
BioCentury | Dec 5, 2024
Management Tracks
Várhelyi to lead health at EU
Plus updates from Nouscom, Eton, Healx, Medipost, Fairjourney, Italfarmaco and Cellino
BioCentury | Nov 27, 2024
Product Development
Biohaven’s Phase III SMA miss: was it the target or the trial design?
BioCentury’s latest Clinical Report also analyzes results from Alector, NewAmsterdam and Pyxis that led shares to slip, and more
BioCentury | Nov 23, 2024
Politics, Policy & Law
Trump 2.0 presents opportunities, threats
A clear understanding of threats and opportunities will be essential as the biopharma industry steps into the second Trump administration
BioCentury | Nov 8, 2024
Editor's Commentary
China biotech and the bear: a Perspective
Deal-making with the West offers a path through uncertain times, but in what position will China biotechs emerge from the bear?
Items per page:
1 - 10 of 103